[HTML][HTML] Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer …
Background In the global phase 3 DESTINY-Breast04 study (NCT03734029), the anti-
human epidermal growth factor 2 (HER2) antibody–drug conjugate trastuzumab deruxtecan …
human epidermal growth factor 2 (HER2) antibody–drug conjugate trastuzumab deruxtecan …
Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with …
DY Chang, CC Lin, TWW Chen, CH Lin, JH Lee… - Molecular Cancer …, 2019 - AACR
Background: Anti-HER2 therapies are beneficial for patients with HER2+ gastric or breast
cancer (BC).[Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is an antibody-drug …
cancer (BC).[Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is an antibody-drug …
Abstract P1-11-01: Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup …
Background: DESTINY-Breast04 demonstrated that the HER2 targeting antibody–drug
conjugate trastuzumab deruxtecan (T-DXd) significantly prolonged progression-free survival …
conjugate trastuzumab deruxtecan (T-DXd) significantly prolonged progression-free survival …
[PDF][PDF] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
S Modi, C Saura, T Yamashita… - San Antonio …, 2020 - cdn.physiciansweekly.com
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive, advanced gastric
or gastroesophageal junction (GEJ) ade Page 1 RESULTS BC, breast cancer; HER2, human …
or gastroesophageal junction (GEJ) ade Page 1 RESULTS BC, breast cancer; HER2, human …
[HTML][HTML] 195P Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive advanced breast cancer: A multicentric Portuguese study
RC Bizarro, MIP Portela, A Teixeira, MQ Pereira… - ESMO Open, 2024 - esmoopen.com
Background Substantial improvement in survival has been seen in HER2+ advanced breast
cancer (ABC) over the past years with the introduction and widespread use of multiple novel …
cancer (ABC) over the past years with the introduction and widespread use of multiple novel …
[HTML][HTML] Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-
HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial …
HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial …
Trastuzumab deruxtecan: first approval
SJ Keam - Drugs, 2020 - Springer
Trastuzumab deruxtecan (ENHERTU®), a HER2-directed antibody and DNA topoisomerase
I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours …
I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours …
Abstract PO2-19-06: An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2 …
S Modi, R Salgado, V Guarneri, D Alagappan… - Cancer Research, 2024 - AACR
Background Approximately 50% of all breast cancer (BC) tumors express low levels of
HER2, defined by HER2 immunohistochemistry (IHC) scores of 1+ or IHC 2+/in situ …
HER2, defined by HER2 immunohistochemistry (IHC) scores of 1+ or IHC 2+/in situ …
Exploring DESTINY: The past, present, and future of Trastuzumab Deruxtecan
A Ali, SL Graff - Current Oncology Reports, 2024 - Springer
Purpose of Review HER2-positive breast cancer accounts for 10–15% of all breast cancers
and fam-trastuzumab deruxtecan (T-DXd) has played a major role in moving the treatment of …
and fam-trastuzumab deruxtecan (T-DXd) has played a major role in moving the treatment of …